永顺生物
(920729)
| 流通市值：5.11亿 | | | 总市值：18.01亿 |
| 流通股本：7750.70万 | | | 总股本：2.73亿 |
| 利润表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 营业总收入 | 47,452,322.97 | 238,174,536.39 | 179,973,670.63 | 121,726,217.01 |
| 营业总成本 | 43,338,273.37 | 206,942,003.57 | 156,149,380.07 | 105,146,428.28 |
| 其他经营收益 | | | | |
| 营业利润 | 5,378,870.13 | 46,290,370.35 | 34,057,129.58 | 21,973,532.74 |
| 利润总额 | 5,412,144.78 | 46,195,892.78 | 33,998,945.33 | 21,932,915.02 |
| 净利润 | 5,083,098.81 | 41,257,977.62 | 30,283,823.27 | 19,720,898.19 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 5,083,098.81 | 41,257,977.62 | 30,283,823.27 | 19,720,898.19 |
| 资产负债表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 流动资产: | | | | |
| 流动资产合计 | 269,250,866.9 | 293,154,987.07 | 612,154,369.03 | 580,319,845.74 |
| 非流动资产: | | | | |
| 非流动资产合计 | 525,038,311.44 | 500,700,529.12 | 178,901,183.26 | 183,065,303.42 |
| 资产总计 | 794,289,178.34 | 793,855,516.19 | 791,055,552.29 | 763,385,149.16 |
| 流动负债: | | | | |
| 流动负债合计 | 105,878,134.82 | 111,316,290.98 | 120,625,556.4 | 105,310,687.34 |
| 非流动负债: | | | | |
| 非流动负债合计 | 6,976,141.51 | 6,875,849.61 | 7,683,849.58 | 8,447,891.19 |
| 负债合计 | 112,854,276.33 | 118,192,140.59 | 128,309,405.98 | 113,758,578.53 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 681,434,902.01 | 675,663,375.6 | 662,746,146.31 | 649,626,570.63 |
| 股东权益合计 | 681,434,902.01 | 675,663,375.6 | 662,746,146.31 | 649,626,570.63 |
| 负债和股东权益合计 | 794,289,178.34 | 793,855,516.19 | 791,055,552.29 | 763,385,149.16 |
| 现金流量表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 50,727,467.76 | 277,217,012.02 | 203,404,467.92 | 131,062,431.38 |
| 经营活动现金流出小计 | 50,437,877.18 | 177,184,316.61 | 128,742,828.94 | 87,711,875.41 |
| 经营活动产生的现金流量净额 | 289,590.58 | 100,032,695.41 | 74,661,638.98 | 43,350,555.97 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 186,166,395.15 | 361,110,466.91 | 311,473,424.09 | 227,812,633.19 |
| 投资活动现金流出小计 | 162,238,200 | 457,540,495.9 | 384,789,205.9 | 274,582,659.9 |
| 投资活动产生的现金流量净额 | 23,928,195.15 | -96,430,028.99 | -73,315,781.81 | -46,770,026.71 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 495,984.32 | 15,514,413.62 | 15,514,413.62 | 15,514,413.62 |
| 筹资活动现金流出小计 | 157,695.18 | 36,166,424.8 | 36,009,534.86 | 35,854,706.28 |
| 筹资活动产生的现金流量净额 | 338,289.14 | -20,652,011.18 | -20,495,121.24 | -20,340,292.66 |
| 汇率变动对现金及现金等价物的影响 | -324,759.84 | -153,330.43 | 31,809.41 | 104,841.04 |
| 现金及现金等价物净增加额 | 24,231,315.03 | -17,202,675.19 | -19,117,454.66 | -23,654,922.36 |
| 期末现金及现金等价物余额 | 43,469,214.02 | 19,237,898.99 | 17,323,119.52 | 12,785,651.82 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -17,202,675.19 | - | -23,654,922.36 |